Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, M. D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Texas Oncol PA, Baylor Sammons Canc Ctr, Dallas, TX USA
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[5] Ctr Leon Berard, F-69373 Lyon, France
[6] Pfizer Oncol, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5042
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Hai-Liang Zhang
    Xi-Nan Sheng
    Xue-Song Li
    Hong-Kai Wang
    Zhi-Hong Chi
    Zhi-Song He
    Ding-Wei Ye
    Jun Guo
    [J]. BMC Cancer, 17
  • [32] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bjarnason, G. A.
    Lin, X.
    Lowenthal, S. Pitman
    Korytowsky, B.
    Matczak, E.
    Oudard, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
  • [33] First-line therapy for metastatic renal cell carcinoma
    Sawhney, Paramvir
    Suyanto, Suyanto
    Michael, Agnieszka
    Pandha, Hardev
    [J]. JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
  • [34] CLINICAL OUTCOMES OF AXITINIB VERSUS SUNITINIB AS A FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN JAPANESE PATIENTS
    Kiso, Yusuke
    Inoue, Takamitsu
    Nara, Taketoshi
    Kanda, Sohei
    Numakura, Kazuyuki
    Tsuruta, Hiroshi
    Saito, Mitsuru
    Narita, Shintaro
    Satoh, Shigeru
    Habuchi, Tomonori
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E874 - E874
  • [35] COST EFFECTIVENESS OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN CHINA
    Shi, Q.
    Yin, H.
    Xuan, J.
    Wu, Y.
    Cheng, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
  • [36] Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Hill, Jerrold W.
    Guo, Min Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [37] Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors
    Motzer, R. J.
    Michaelson, M. D.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 301 - 301
  • [38] The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT)
    Ko, Jenny J.
    Xie, Wanling
    Heng, Daniel Yick Chin
    Kroeger, Nils
    Lee, Jae-Lyun
    Rini, Brian I.
    Knox, Jennifer J.
    Bjarnason, Georg A.
    Harshman, Lauren Christine
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Smoragiewicz, Martin
    Donskov, Frede
    Bamias, Aristotelis
    Wood, Lori
    Ernst, D. Scott
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
    Abd Ghafar, Nahjatul Kursyiah
    Alip, Adlinda
    Ong, Teng Aik
    Yap, Ning Yi
    Saad, Marniza
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1303 - 1311
  • [40] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    [J]. ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
12345